成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Immunology/Inflammation Autophagy
  3. COX Autophagy
  4. Naproxen

Naproxen  (Synonyms: 萘普生; (S)-Naproxen)

目錄號: HY-15030 純度: 99.98%
COA 產(chǎn)品使用指南 技術支持

Naproxen是COX-1 和 COX-2 的抑制劑，在細胞試驗中 IC50 值分別為8.72 和5.15 μM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Naproxen Chemical Structure

Naproxen Chemical Structure

CAS No. : 22204-53-1

1.  客戶無需承擔相應的運輸費用。

2.  同一機構（單位）同一產(chǎn)品試用裝僅限申領一次，同一機構（單位）一年內(nèi)

     可免費申領三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥500
In-stock
500 mg ￥400
In-stock
5 g ￥600
In-stock
10 g ￥960
In-stock
50 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Naproxen:

查看 COX 亞型特異性產(chǎn)品:

  • 生物活性

  • 實驗參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.

IC50 & Target[1]

COX-2

5.65 μM (IC50)

COX-1

9.55 μM (IC50)

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 CC50
1.4 mM
Compound: Naproxen
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 30028133]
BGC-823 IC50
> 50 μM
Compound: Naproxen
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
BXPC-3 IC50
2450 μM
Compound: 1, NAP
Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay
[PMID: 24273639]
Caco-2 IC50
> 50 μM
Compound: Naproxen
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
COS-7 IC50
> 1000 μM
Compound: Naproxen
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
DU-145 IC50
> 100 μM
Compound: 3; Nap
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
Erythrocyte EC50
756 μM
Compound: NPX
Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay
Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay
[PMID: 25863493]
HCT-15 IC50
> 1000 μM
Compound: Naproxen
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
HT-29 IC50
> 100 μM
Compound: 3; Nap
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
HT-29 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
2600 μM
Compound: 1, NAP
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
[PMID: 24273639]
Jurkat IC50
2550 μM
Compound: 1, NAP
Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay
[PMID: 24273639]
K562 IC50
181 μM
Compound: Naproxen
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
MCF7 IC50
> 100 μM
Compound: 3; Nap
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
MCF7 IC50
> 1000 μM
Compound: Naproxen
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
MCF7 IC50
> 400 μM
Compound: Naproxen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 33743356]
MCF7 IC50
> 50 μM
Compound: Naproxen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
MCF7 IC50
2385 μM
Compound: 1, NAP
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
[PMID: 24273639]
MDA-MB-231 IC50
> 400 μM
Compound: Naproxen
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 33743356]
MDA-MB-231 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
MDA-MB-231 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
MDA-MB-231 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
MDCK CC50
1 mM
Compound: Naproxen
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method
[PMID: 30028133]
MDCK CC50
1.4 mM
Compound: Naproxen
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
[PMID: 30028133]
PANC-1 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
PANC-1 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
PANC-1 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
PC-3 IC50
> 1000 μM
Compound: Naproxen
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
PC-3 IC50
> 50 μM
Compound: Naproxen
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
SK-LU-1 IC50
> 1000 μM
Compound: Naproxen
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
U-251 IC50
> 1000 μM
Compound: Naproxen
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
UACC-903 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
UACC-903 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
UACC-903 IC50
> 50 μM
Compound: Nap
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
體外研究
(In Vitro)

Naproxen etemesil 是一種親脂性、非酸性、無活性的 Naproxen 前藥，一旦被吸收就會水解成具有藥理活性的 Naproxen。Naproxen 是眾所周知的非甾體抗炎藥。Naproxen 在完整細胞中是近似等效的 COX-1 和 COX-2 抑制劑，IC50 分別為 2.2 μg/mL 和 1.3 μg/mL[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究
(In Vivo)

Naproxen 在博來霉素誘導的肺纖維化小鼠模型中發(fā)揮抗炎和抗纖維化作用。Naproxen 還下調(diào) TGF-β 水平和 Smad3/4 復合物形成[2]。Naproxen 顯示出抑制疼痛、發(fā)熱和 PGE2 的時間過程，具有相似的效力 (IC50=27、40、13 μM)[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

230.26

Formula

C14H14O3
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

萘普生；奈普生；甲氧萘丙酸
運輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細胞實驗： 

DMSO 中的溶解度 : ≥ 100 mg/mL (434.29 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H2O 中的溶解度 : 75 mg/mL (325.72 mM; 超聲加熱助溶)

* "≥" means soluble, but saturation unknown.

配制儲備液
濃度 溶劑體積 質量 1 mg 5 mg 10 mg
1 mM 4.3429 mL 21.7146 mL 43.4292 mL
5 mM 0.8686 mL 4.3429 mL 8.6858 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用，-20°C儲存時，請在1年內(nèi)使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗：

請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.86 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (10.86 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： PBS

    Solubility: 2 mg/mL (8.69 mM); 澄清溶液; 超聲助溶

掃碼獲得
動物溶解方案

動物溶解方案計算器
請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實驗過程有損耗，建議您多配一只動物的量
純度 & 產(chǎn)品資料

純度: 99.98%

參考文獻
Cell Assay
[1]

BAEC are incubated for 30 min with Naproxen (0.1 ng/mL to 1 mg/mL). Arachidonic acid (30 μM) is then added, and the cells are incubated for a further 15 min at 37°C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF,a, PGE2, thromboxane B2, or PGF2a[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2][3]

Rats[3]

To measure the analgesic effects of naproxen in a carrageenaninduced model of monoarthritis, Male Sprague–Dawley rats (n=48, 217±28 g) are randomly divided into four groups of 12 by an internally developed computer program, allowing the blind performance of the behavioral experiment. To induce hyperalgesia by inflammation, animals in groups 1B, 1C, and 1D receive a 40-μL intra-articular injection of a saline solution containing 7.5 mg/mL carrageenan in the left hind limb under isoflurane anesthesia (time=?1 h). Animals in group 1A receive no injection. After 1 h (time=0) the animals in groups 1A, 1B, 1C, and 1D receive oral doses of naproxen in saline of 0, 0, 7.5 and 30 μmol/kg, respectively. The doses and time points of measurements are selected on the basis of simulations predicting measuring a full concentration-effect relationship within the time-span of the experiment[3].

Mice[2]

Bleomycin (0.05 IU) is instilled intratracheally to C57BL/6 mice, which are then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, is assessed, and lung specimens are processed for inflammation, oxidative stress, and fibrosis markers[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用，-20°C儲存時，請在1年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 4.3429 mL 21.7146 mL 43.4292 mL 108.5729 mL
5 mM 0.8686 mL 4.3429 mL 8.6858 mL 21.7146 mL
10 mM 0.4343 mL 2.1715 mL 4.3429 mL 10.8573 mL
15 mM 0.2895 mL 1.4476 mL 2.8953 mL 7.2382 mL
20 mM 0.2171 mL 1.0857 mL 2.1715 mL 5.4286 mL
25 mM 0.1737 mL 0.8686 mL 1.7372 mL 4.3429 mL
30 mM 0.1448 mL 0.7238 mL 1.4476 mL 3.6191 mL
40 mM 0.1086 mL 0.5429 mL 1.0857 mL 2.7143 mL
50 mM 0.0869 mL 0.4343 mL 0.8686 mL 2.1715 mL
60 mM 0.0724 mL 0.3619 mL 0.7238 mL 1.8095 mL
80 mM 0.0543 mL 0.2714 mL 0.5429 mL 1.3572 mL
100 mM 0.0434 mL 0.2171 mL 0.4343 mL 1.0857 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機構名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Naproxen
目錄號：
HY-15030
需求量：
我們的 Cookie 政策

我們使用 Cookies 和類似技術以提高網(wǎng)站的性能和提升您的瀏覽體驗，部分功能也使用 Cookies 幫助我們更好地理解您的需求，為您提供相關的服務。 如果您有任何關于我們?nèi)绾翁幚砟鷤€人信息的疑問，請閱讀我們的《隱私聲明》。